# Peptide Arrays as Tools for Unraveling Tumor Microenvironments and Drug Discovery in Oncology

## TL;DR

Peptide arrays are powerful tools for studying tumor environments, identifying cancer biomarkers, and developing personalized cancer therapies.

## Contribution

This review highlights recent advances in peptide array technology for oncology, including drug screening and AI-driven analysis of tumor microenvironments.

## Key findings

- Peptide arrays enable high-throughput screening of peptides to study tumor microenvironment interactions.
- Peptide chip mapping helps identify metastasis-related biomarkers and cell-adhesion peptides.
- AI-driven peptide array analysis can determine tumor origin and metastatic state, aiding precision cancer approaches.

## Abstract

What are the main findings?
Recent achievements report on the application of peptide array technology in the study of tumor microenvironment.

Recent achievements report on the application of peptide array technology in the study of tumor microenvironment.

What are the implications of the main findings?
Peptide chip mapping of tumor microenvironment interactions can help identify metastasis-related biomarkers.Peptide arrays enable drug screening for personalized therapies.

Peptide chip mapping of tumor microenvironment interactions can help identify metastasis-related biomarkers.

Peptide arrays enable drug screening for personalized therapies.

Peptide arrays represent a powerful tool for investigating a wide application field for biomedical questions. This review summarizes recent applications of peptide chips in oncology, with a focus on tumor microenvironment, metastasis, and drug mechanism of action for various cancer types. These high-throughput platforms enable the simultaneous screening of thousands of peptides. We report on recent achievements in peptide array technology for tumor microenvironments, an enhanced ability to decipher complex cancer-related signaling pathways, and characterization of cell-adhesion-mediating peptides. Furthermore, we highlight the applications in high-throughput drug screenings for development of immune therapies, e.g., the development of novel neoantigen therapies of glioblastoma. Moreover, epigenetic profiling using peptide arrays has uncovered new therapeutic targets across various cancer types with clinical impact. In conclusion, we discuss artificial intelligence-driven peptide array analysis as a tool to determine tumor origin and metastatic state, potentially transforming diagnostic approaches. These innovations promise to accelerate the development of precision cancer approaches.